Gillian Barratt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gillian Barratt has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- François-Xavier Legrand
Université Paris-Saclay, CNRS, Institut Galien Paris-Saclay, 91400 Orsay, France
2 shared publications Philippe M. Loiseau
Université Paris-Saclay, CNRS, BioCIS, 91400 Orsay, France
2 shared publications- Sébastien Pomel
Université Paris-Saclay, CNRS BioCIS, 91400 Orsay, France
2 shared publications Antonio Lipa Castro
Institut Galien Paris-Saclay, UMR CNRS 8612, Faculty of Pharmacy, Univ. Paris-Saclay, Bâtiment Henri MOISSAN, 17 avenue des Sciences, 91400 Orsay, France
1 shared publicationAntonio Lipa-Castro
Université Paris-Saclay, CNRS, Institut Galien Paris-Saclay, 92290 Châtenay-Malabry, France
1 shared publicationAudrey Solgadi
Université Paris-Saclay, Inserm, CNRS, Ingénierie et Plateformes au Service de l'Innovation Thérapeutique, 92296 Châtenay-Malabry, France
1 shared publication
Latest Publications
- Open Access
- 4 December 2025
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 689, 126439
Are hydrophilic deep eutectic solvents a potential vehicle for topical delivery of Amphotericin B against cutaneous leishmaniasis? An investigation of physicochemical properties, tolerability and antileishmanial efficacy
- 4 December 2025
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 689, 126439
Open AccessAre hydrophilic deep eutectic solvents a potential vehicle for topical delivery of Amphotericin B against cutaneous leishmaniasis? An investigation of physicochemical properties, tolerability and antileishmanial efficacy
- Open Access
The Potential of 2-Substituted Quinolines as Antileishmanial Drug Candidates
There is a need for new, cost-effective drugs to treat leishmaniasis. A strategy based on traditional medicine practiced in Bolivia led to the discovery of the 2-substituted quinoline series as a source of molecules with antileishmanial activity and low toxicity. This review documents the development of the series from the first isolated natural compounds through several hundred synthetized molecules to an optimized compound exhibiting an in vitro IC50 value of 0.2 µM against Leishmania donovani, and a selectivity index value of 187, together with in vivo activity on the L. donovani/hamster model. Attempts to establish structure–activity relationships are described, as well as studies that have attempted to determine the mechanism of action. For the latter, it appears that molecules of this series act on multiple targets, possibly including the immune system, which could explain the observed lack of drug resistance after in vitro drug pressure. We also show how nanotechnology strategies could valorize these drugs through adapted formulations and how a mechanistic targeting approach could generate new compounds with increased activity.
Open AccessThe Potential of 2-Substituted Quinolines as Antileishmanial Drug Candidates
There is a need for new, cost-effective drugs to treat leishmaniasis. A strategy based on traditional medicine practiced in Bolivia led to the discovery of the 2-substituted quinoline series as a source of molecules with antileishmanial activity and low toxicity. This review documents the development of the series from the first isolated natural compounds through several hundred synthetized molecules to an optimized compound exhibiting an in vitro IC50 value of 0.2 µM against Leishmania donovani, and a selectivity index value of 187, together with in vivo activity on the L. donovani/hamster model. Attempts to establish structure–activity relationships are described, as well as studies that have attempted to determine the mechanism of action. For the latter, it appears that molecules of this series act on multiple targets, possibly including the immune system, which could explain the observed lack of drug resistance after in vitro drug pressure. We also show how nanotechnology strategies could valorize these drugs through adapted formulations and how a mechanistic targeting approach could generate new compounds with increased activity.
- 1 December 2021
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 610, 121225
Cochleate drug delivery systems: An approach to their characterization
- 1 December 2021
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 610, 121225
Cochleate drug delivery systems: An approach to their characterization
- 20 October 2020
- Published by Springer Nature
- p. 41-102
Deep Eutectic Solvents for Innovative Pharmaceutical Formulations
- 20 October 2020
- Published by Springer Nature
- p. 41-102
Deep Eutectic Solvents for Innovative Pharmaceutical Formulations
- 1 June 2020
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 584, 119391
Cyclodextrin complexation studies as the first step for repurposing of chlorpromazine
- 1 June 2020
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 584, 119391
Cyclodextrin complexation studies as the first step for repurposing of chlorpromazine
- 19 April 2016
- Published by Taylor & Francis
- p. 117-134
An Original Lipid Complex System for Amphotericin B
- 19 April 2016
- Published by Taylor & Francis
- p. 117-134
An Original Lipid Complex System for Amphotericin B
- 1 October 2011
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 418 (1) , 3-5
Takeru Higuchi, the man and the scientist
- 1 October 2011
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 418 (1) , 3-5
Takeru Higuchi, the man and the scientist
- 1 September 2009
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 379 (2) , 199-200
Preface
- 1 September 2009
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 379 (2) , 199-200
Preface
- 1 July 2001
- Published by Taylor & Francis in Pathogens and Global Health
- Vol. 95 (5) , 529-533
The antileishmanial properties of surface-modified, primaquine-loaded nanocapsules tested against intramacrophagic Leishmania donovani amastigotes in vitro
- 1 July 2001
- Published by Taylor & Francis in Pathogens and Global Health
- Vol. 95 (5) , 529-533
The antileishmanial properties of surface-modified, primaquine-loaded nanocapsules tested against intramacrophagic Leishmania donovani amastigotes in vitro